Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions. Central to its pipeline is ALLN-346, an innovative enzyme designed to degrade urate, targeting hyperuricemia and gout in individuals with advanced chronic kidney disease.